Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Normal 9 Saline

Research Leaders

5 sponsors active, led by SAb Biotherapeutics, Inc.

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04170829Phase 1CompletedPrimary

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)

NCT02788188Phase 1CompletedPrimary

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

Showing all 2 trials

Research Network

Common Treatments

  • Normal 9 Saline1
  • Chadox1 Mers1
  • Sab3011

Active Sponsors

  • SAb Biotherapeutics, Inc.1
  • Naval Medical Research Center1
  • King Abdullah International Medical Research Center1
  • University of Oxford1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Activity Timeline